363 related articles for article (PubMed ID: 28570014)
1. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.
Ferrer-Font L; Arias-Ramos N; Lope-Piedrafita S; Julià-Sapé M; Pumarola M; Arús C; Candiota AP
NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28570014
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumour immune response in GL261 glioblastoma generated by Temozolomide Immune-Enhancing Metronomic Schedule monitored with MRSI-based nosological images.
Wu S; Calero-Pérez P; Villamañan L; Arias-Ramos N; Pumarola M; Ortega-Martorell S; Julià-Sapé M; Arús C; Candiota AP
NMR Biomed; 2020 Apr; 33(4):e4229. PubMed ID: 31926117
[TBL] [Abstract][Full Text] [Related]
3. Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model.
Wu J; Waxman DJ
Cancer Lett; 2014 Oct; 353(2):272-80. PubMed ID: 25069038
[TBL] [Abstract][Full Text] [Related]
4. Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators.
Wu J; Jordan M; Waxman DJ
BMC Cancer; 2016 Aug; 16():623. PubMed ID: 27515027
[TBL] [Abstract][Full Text] [Related]
5. Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma.
Delgado-Goñi T; Julià-Sapé M; Candiota AP; Pumarola M; Arús C
NMR Biomed; 2014 Nov; 27(11):1333-45. PubMed ID: 25208348
[TBL] [Abstract][Full Text] [Related]
6. Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice.
Ferrer-Font L; Villamañan L; Arias-Ramos N; Vilardell J; Plana M; Ruzzene M; Pinna LA; Itarte E; Arús C; Candiota AP
Pharmaceuticals (Basel); 2017 Feb; 10(1):. PubMed ID: 28208677
[TBL] [Abstract][Full Text] [Related]
7. Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8
Wu J; Waxman DJ
Oncoimmunology; 2015 Apr; 4(4):e1005521. PubMed ID: 26137402
[TBL] [Abstract][Full Text] [Related]
8. MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis.
Delgado-Goñi T; Ortega-Martorell S; Ciezka M; Olier I; Candiota AP; Julià-Sapé M; Fernández F; Pumarola M; Lisboa PJ; Arús C
NMR Biomed; 2016 Jun; 29(6):732-43. PubMed ID: 27061401
[TBL] [Abstract][Full Text] [Related]
9. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
[TBL] [Abstract][Full Text] [Related]
10. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
[TBL] [Abstract][Full Text] [Related]
11. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model.
Banissi C; Ghiringhelli F; Chen L; Carpentier AF
Cancer Immunol Immunother; 2009 Oct; 58(10):1627-34. PubMed ID: 19221744
[TBL] [Abstract][Full Text] [Related]
12. Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas.
Kim JT; Kim JS; Ko KW; Kong DS; Kang CM; Kim MH; Son MJ; Song HS; Shin HJ; Lee DS; Eoh W; Nam DH
Oncol Rep; 2006 Jul; 16(1):33-9. PubMed ID: 16786120
[TBL] [Abstract][Full Text] [Related]
13. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
14. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
15. Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro.
Sun C; Yu Y; Wang L; Wu B; Xia L; Feng F; Ling Z; Wang S
J Exp Clin Cancer Res; 2016 Feb; 35():32. PubMed ID: 26872471
[TBL] [Abstract][Full Text] [Related]
16. A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
Towner RA; Ihnat M; Saunders D; Bastian A; Smith N; Pavana RK; Gangjee A
BMC Cancer; 2015 Jul; 15():522. PubMed ID: 26177924
[TBL] [Abstract][Full Text] [Related]
17. Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model.
Dai B; Qi N; Li J; Zhang G
Biochem Biophys Res Commun; 2018 Jul; 501(4):871-876. PubMed ID: 29758196
[TBL] [Abstract][Full Text] [Related]
18. Pulsed versus conventional radiation therapy in combination with temozolomide in a murine orthotopic model of glioblastoma multiforme.
Lee DY; Chunta JL; Park SS; Huang J; Martinez AA; Grills IS; Krueger SA; Wilson GD; Marples B
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):978-85. PubMed ID: 23845846
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of temozolomide for recurrent glioblastoma multiforme.
Chen C; Xu T; Lu Y; Chen J; Wu S
Eur J Neurol; 2013 Feb; 20(2):223-30. PubMed ID: 22680781
[TBL] [Abstract][Full Text] [Related]
20. EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide.
Cominelli M; Grisanti S; Mazzoleni S; Branca C; Buttolo L; Furlan D; Liserre B; Bonetti MF; Medicina D; Pellegrini V; Buglione M; Liserre R; Pellegatta S; Finocchiaro G; Dalerba P; Facchetti F; Pizzi M; Galli R; Poliani PL
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25739547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
